1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Boehringer Ingelheim Introduces US FDA Approved VETMEDIN Solution for CHF in Dogs

27 Nov 2024
Admin
News Article

Boehringer Ingelheim Introduces US FDA Approved VETMEDIN Solution for CHF in Dogs

Overview

Boehringer Ingelheim, a global leader in animal health, launched VETMEDIN Solution, the first oral solution approved by the US Food and Drug Administration (FDA) for the management of congestive heart failure (CHF) in dogs due to MMVD or DCM.

Heart Disease in Dogs

Unfortunately, heart disease in dogs is common, affecting approximately 10 percent of dogs in their lifetime.
Most frequently, dogs are affected by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM), both which may progress to CHF, characterized by the inability of the heart to effectively pump blood throughout the body.

Convinience for Pet Owners

Now pet owners have a convenient, new management option to support the hearts of dogs with CHF: a liquid version of VETMEDIN, one of the leading canine cardiology medications in the world.
Previous studies have shown that VETMEDIN could help increase the survival time and quality of life in dogs due to MMVD or DCM.

Words from the VP: Boehringer Ingelheim

“We continue to deliver new innovations rooted in robust clinical evidence to help more pets,” said Daniel Watkins, VP US Pet Business, Boehringer Ingelheim.
“We know some dogs and pet owners may prefer a liquid medication, especially for smaller dogs. With VETMEDIN Solution, an easy-to-use liquid formulation, we can help more dogs with heart disease have longer survival and live better lives.”

The VETMEDIN Solution

VETMEDIN Solution, now available in the US, provides the same dual mode of action as VETMEDIN chewable tablets.
The flavourless, twice-daily liquid oral solution should be administered directly into the dog’s mouth.
Since VETMEDIN was first introduced 25 years ago, dogs and their owners around the world have enjoyed more than 1 million years of additional life to love.
VETMEDIN chewable tablets are approved for the management of the signs of mild, moderate, or severe CHF in dogs due to clinical MMVD or DCM.
VETMEDIN chewable tablets are indicated for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.

VETMEDIN-CA1

Boehringer Ingelheim also offers VETMEDIN-CA1 (pimobendan), which has FDA conditional approval for use in dogs with Stage B2 preclinical MMVD – which may enable a delay in the onset of heart failure symptoms.

Boehringer Ingelheim Work for Innovation

Boehringer Ingelheim provides innovation for preventing and treating diseases in animals.
The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments.

About the Compny: Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health.
As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies in areas of high unmet medical need.